Skip to main content
Only direct cytotoxic targets are shown
Gene
Drug Category
Drug Class
Download CSV
Gene NCT ID Antigen/Ligand Binding Type Drug Name Drug NCI Concept Drug Category Drug Class Drug Description Drug Mechanism of Action Target Cytotoxicity Mechanism Disease Disease Type Tissue OncoTree Main Type OncoTree Name Annotation Status
EGFR NCT06120140 EGFR other Lazertinib C148147 SMALL MOLECULE DRUG Inhibitor Oral third-generation irreversible EGFR tyrosine kinase inhibitor active against Exon 19 deletion/L858R and T790M mutations. Oral third-generation irreversible EGFR tyrosine kinase inhibitor that selectively and covalently targets mutant EGFR (Exon 19 deletion, L858R, T790M), blocking downstream signaling and inducing death of EGFR-mutant tumor cells while sparing wild-type EGFR; penetrates the blood–brain barrier. Irreversible covalent inhibition of mutant EGFR kinase blocks downstream survival pathways (e.g., MAPK/PI3K-AKT), inducing apoptosis of EGFR-mutant tumor cells while sparing wild-type EGFR. Carcinoma, Non-Small-Cell Lung CANCER Lung Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer ai
EGFR NCT06120140 EGFR other Lazertinib C148147 SMALL MOLECULE DRUG Inhibitor Oral third-generation irreversible EGFR tyrosine kinase inhibitor active against Exon 19 deletion/L858R and T790M mutations. Oral third-generation irreversible EGFR tyrosine kinase inhibitor that selectively and covalently targets mutant EGFR (Exon 19 deletion, L858R, T790M), blocking downstream signaling and inducing death of EGFR-mutant tumor cells while sparing wild-type EGFR; penetrates the blood–brain barrier. Irreversible inhibition of mutant EGFR kinase (e.g., Exon 19 del, L858R, T790M) blocks downstream survival signaling (PI3K/AKT, MAPK), leading to growth arrest and apoptosis of EGFR-mutant tumor cells; minimal effect on wild-type EGFR. Carcinoma, Non-Small-Cell Lung CANCER Lung Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer ai
EGFR NCT06120140 EGFR other Lazertinib C148147 SMALL MOLECULE DRUG Inhibitor Oral third-generation irreversible EGFR tyrosine kinase inhibitor active against Exon 19 deletion/L858R and T790M mutations. Oral third-generation irreversible EGFR tyrosine kinase inhibitor that selectively and covalently targets mutant EGFR (Exon 19 deletion, L858R, T790M), blocking downstream signaling and inducing death of EGFR-mutant tumor cells while sparing wild-type EGFR; penetrates the blood–brain barrier. Small-molecule irreversible inhibition of mutant EGFR (e.g., Exon 19 deletion, L858R, T790M) blocks downstream survival signaling, triggering apoptosis of EGFR-mutant tumor cells; not immune mediated. Carcinoma, Non-Small-Cell Lung CANCER Lung Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer ai
MS4A1 NCT06249191 CD20 antigen recognition Mosunetuzumab C129691 BISPECIFIC T ENGAGER Engager Bispecific monoclonal antibody (CD20×CD3) T‑cell engager that redirects T cells to kill CD20+ B cells. Humanized bispecific CD20xCD3 monoclonal antibody that binds CD20 on B cells and CD3 on T cells, crosslinking them to activate TCR/CD3 signaling and form cytolytic synapses, leading to perforin/granzyme-mediated killing of CD20+ malignant B cells. Bispecific CD20xCD3 T‑cell engager redirects T cells to CD20+ cells, forming a cytolytic synapse and inducing perforin/granzyme-mediated killing. High Grade B-Cell Lymphoma CANCER Lymphoid Non-Hodgkin Lymphoma, B Cell High-Grade B-Cell Lymphoma, NOS ai
MS4A1 NCT06350318 CD20 antigen recognition Rituximab C1702 CYTOTOXIC ANTIBODY Inhibitor Type I anti-CD20 monoclonal antibody that depletes CD20-positive B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis; given intravenously or subcutaneously. Chimeric type I anti-CD20 monoclonal antibody that binds CD20 on B cells and induces their depletion via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct apoptosis. Rituximab binds CD20 on B cells and induces killing via Fc-mediated ADCC by NK cells/macrophages, complement-dependent cytotoxicity (MAC formation), and can trigger direct apoptotic signaling upon CD20 crosslinking. B-Cell Lymphoma CANCER Lymphoid Non-Hodgkin Lymphoma, B Cell Mature B-Cell Neoplasms ai
Displaying 2921 - 2925 of 3741